You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Express Scripts
Boehringer Ingelheim
McKinsey
Medtronic

Last Updated: March 2, 2021

DrugPatentWatch Database Preview

Caspofungin acetate - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for caspofungin acetate and what is the scope of patent protection?

Caspofungin acetate is the generic ingredient in two branded drugs marketed by Merck, Cipla, Fresenius Kabi Usa, Gland Pharma Ltd, Jiangsu Hengrui Med, Mylan Labs Ltd, and Xellia Pharms Aps, and is included in seven NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Caspofungin acetate has fourteen patent family members in fourteen countries.

There are eight drug master file entries for caspofungin acetate. Eight suppliers are listed for this compound.

Drug Prices for caspofungin acetate

See drug prices for caspofungin acetate

Recent Clinical Trials for caspofungin acetate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
European Organisation for Research and Treatment of Cancer - EORTCPhase 3
Children's Oncology GroupPhase 3
Merck Sharp & Dohme Corp.Phase 3

See all caspofungin acetate clinical trials

Pharmacology for caspofungin acetate
Paragraph IV (Patent) Challenges for CASPOFUNGIN ACETATE
Tradename Dosage Ingredient NDA Submissiondate
CANCIDAS POWDER;INTRAVENOUS caspofungin acetate 021227 2009-06-26

US Patents and Regulatory Information for caspofungin acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cipla CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 209489-002 Jul 12, 2018 DISCN No No   Start Trial   Start Trial   Start Trial
Gland Pharma Ltd CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 207092-001 Sep 29, 2017 AP RX No No   Start Trial   Start Trial   Start Trial
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-001 Jan 26, 2001 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for caspofungin acetate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-002 Jan 26, 2001   Start Trial   Start Trial
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-001 Jan 26, 2001   Start Trial   Start Trial
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-001 Jan 26, 2001   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for caspofungin acetate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0620232 SPC/GB02/002 United Kingdom   Start Trial A SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB02/002 GRANTED TO MERCK SHARP + DOHME, CORP IN RESPECT OF THE PRODUCT CASPOFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE, WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 5919 DATED 30 OCTOBER 2002 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 24 OCTOBER 2016.
0620232 2001/029 Ireland   Start Trial PRODUCT NAME: CASPOFUNGIN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024; PAEDIATRIC INV. PLAN: P/30/2008
0620232 01C0054 France   Start Trial PRODUCT NAME: CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001 20011024
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Dow
Boehringer Ingelheim
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.